Array Bridge provides products and services that address two important areas in the development of biologics: biosimilar drug comparability analysis and impurity analysis. Array Bridge has developed "antibody arrays" to measure biosimilar drug comparability at the molecular level, providing a measurement of biosimilar conformational comparability. This antibody array-based technology can be used at all stages of biosimilar development, from cell line selection and process development to clinical testing and product release. For impurity analysis, the company provides ELISA kits and reagents for Host Cell Protein quantitation and Western Blot analysis.